Hexarelin Research

Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.

Massoud AF, Hindmarsh PC, Brook CG · J Clin Endocrinol Metab (1996)

Non-parametric deconvolution provides an objective assessment of GH responsiveness to GH-releasing stimuli in normal subjects.

Sartorio A, De Nicolao G, Pizzini G, Liberati D · Clin Endocrinol (Oxf) (1997)

The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.

Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM · J Clin Endocrinol Metab (1999)

Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess.

Giustina A, Bussi AR, Deghenghi R, Imbimbo B, Licini M, Poiesi C · J Endocrinol (1995)

Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.

Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R · Clin Endocrinol (Oxf) (1997)

The effect of an opiate antagonist on the hormonal changes induced by hexarelin.

Korbonits M, Trainer PJ, Besser GM · Clin Endocrinol (Oxf) (1995)

Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.

Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R · J Clin Endocrinol Metab (1994)

The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.

Massoud AF, Hindmarsh PC, Matthews DR, Brook CG · Clin Endocrinol (Oxf) (1996)

Growth hormone-releasing activity of hexarelin in humans. A dose-response study.

Imbimbo BP, Mant T, Edwards M, Amin D, Dalton N, Boutignon F · Eur J Clin Pharmacol (1994)

Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome.

Coiro V, Volpi R, Capretti L, Caffarri G, Chiodera P · J Intern Med (2000)

Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.

Arvat E, Maccagno B, Ramunni J, Di Vito L, Broglio F, Deghenghi R · Neuroendocrinology (1997)

Acute administration of hexarelin stimulates GH secretion during day and night in normal men.

Loche S, Colao A, Cappa M, Ferone D, Merola B, Faedda A · Clin Endocrinol (Oxf) (1997)

Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man.

Arvat E, Gianotti L, Ramunni J, DiVito L, Deghenghi R, Camanni F · J Endocrinol Invest (1996)

Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.

Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R · Metabolism (1997)

Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients.

Ciccarelli E, Grottoli S, Razzore P, Gianotti L, Arvat E, Deghenghi R · Clin Endocrinol (Oxf) (1996)

GH responsiveness to repeated GHRH or hexarelin administration in normal adults.

Sartorio A, Conti A, Ferrero S, Spada A, Faglia G · J Endocrinol Invest (1995)

Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans.

Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M · J Clin Endocrinol Metab (2001)

Hexarelin induced growth hormone release is influenced by exogenous growth hormone.

Massoud AF, Hindmarsh PC, Brook CG · Clin Endocrinol (Oxf) (1995)

Does desensitization to hexarelin occur?

In plain English: These results show that attenuation of the GH response after long-term hexarelin therapy is partial and reversible.

Rahim A, Shalet SM · Growth Horm IGF Res (1998)

Orally active growth hormone secretagogues: state of the art and clinical perspectives.

In plain English: The effect of GHS is partially desensitized but prolonged, intermittent oral administration increases insulin-like growth factor I (IGF-I) levels.

Ghigo E, Arvat E, Camanni F · Ann Med (1998)